Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 19/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14119996 | 0.95 | HPGDS (0.72) | HPGDS | |
| SCHEMBL14119653 | 0.91 | HPGDS (0.69) | HPGDS | |
| SCHEMBL23000066 | 0.87 | HPGDS (0.64) | HPGDSCYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL28514 | 0.81 | HPGDS (1.00) | HPGDS | |
| SCHEMBL14119527 | 0.81 | HPGDS (0.69) | HPGDS | |
| SCHEMBL14119517 | 0.80 | HPGDS (0.72) | HPGDS | |
| SCHEMBL14119564 | 0.80 | HPGDS (0.59) | HPGDS | |
| SCHEMBL459764 | 0.80 | HPGDS (0.64) | HPGDS | |
| SCHEMBL28039 | 0.79 | HPGDS (1.00) | HPGDS | |
| SCHEMBL14119487 | 0.78 | HPGDS (0.63) | HPGDSCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782648-B1 | PROSTAGLANDIN D2 PRODUCTION INHIBITORS AS PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIV CORPORATION TOKYO UNIV OF AGRICULTURE AND TECHNOLOGY (JP) | 2024-09-18 | — | — | EP | claimed |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2021-06-03 | — | — | US | claimed |
| EP-3782648-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | National University Corporation Tokyo University of Agriculture and Technology (JP) | 2021-02-24 | — | — | EP | claimed |
| CN-111989119-A | Prophylactic and therapeutic agent for sarcopenia | 国立大学法人东京农工大学 | 2020-11-24 | — | — | CN | claimed |
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | claimed |
| CN-102712626-B | Piperazine compounds having PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO LTD | 2014-09-17 | — | — | CN | claimed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | claimed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | claimed |
| CN-102712626-A | Piperazine compounds having PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO LTD | 2012-10-03 | — | — | CN | claimed |
| EP-3782648-B1 | PROSTAGLANDIN D2 PRODUCTION INHIBITORS AS PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIV CORPORATION TOKYO UNIV OF AGRICULTURE AND TECHNOLOGY (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-11883410-B2 | Preventative and therapeutic agents for sarcopenia | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLGY (JP) | 2024-01-30 | — | — | US | disclosed |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2021-06-03 | — | — | US | disclosed |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2021-06-03 | — | — | US | disclosed |
| EP-3782648-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | National University Corporation Tokyo University of Agriculture and Technology (JP) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019203296-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | 国立大学法人東京農工大学 | 2019-10-24 | — | — | WO | disclosed |
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| CN-102712626-B | Piperazine compounds having PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO LTD | 2014-09-17 | — | — | CN | disclosed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| CN-102712626-A | Piperazine compounds having PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO LTD | 2012-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883410-B2 | Preventative and therapeutic agents for sarcopenia | CPT1B, TNNC1, MTPN | HPGDS 32/4885CYP1A2 1085/4885CYP2D6 2749/4885 |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | GRIK5, GRK5, KCNJ5 | HPGDS 14/4885CYP1A2 1241/4885CYP2D6 966/4885 |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | CPT1B, TNNC1, MTPN | HPGDS 32/4885CYP1A2 1085/4885CYP2D6 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.